Management Team

Dr. Wang joined Steminent with abundant scientific expertise and experiences in research, industrial translations, and management. Ling-Mei was a researcher of NIH and Van Andel Research Institute in her early career with keen interests in oncology and cellular biology. She was in various research and management positions in both public and private sectors. Prior to Steminent, Dr. Wang was VP of CHO Pharma.

Bill is a senior executive with over 25 years of business leadership, business development, and management experience in the biopharmaceutical industry. Prior to working with Steminent, Milligan served as Chief Business Officer for Migenix Inc., CEO / Director for Cytran Inc., and CEO / Director for Intellivax International Inc. in the biotech sector. In the pharmaceutical sector, his roles included management positions as VP New Product Planning, VP Business Development, VP Sales Division, and VP BioMedical Division for Hoffman-La Roche, and Product Manager for Eli Lilly. Milligan received a BSc in Biology from the University of Calgary and Business Management education at Ryerson University in Toronto. He currently serves as the Chair for the Business Models and Investment Committee of the International Society of Cellular Therapy.